Multidose Inhaler Launched for Patients with COPD
Starting on October 21st, aclidinium bromide and formoterol fumarate (DUAKLIR PRESSAIR, Circassia) will be available for the maintenance treatment of patients with COPD.
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death due to disease in the United States. According to the American Lung Association, more than 11 million people have been diagnosed with COPD, but millions more may have the disease without knowing it.
COPD causes serious long-term disability and early death, and the number of people dying from the condition is growing.
For the maintenance treatment of patients with COPD, aclidinium bromide and formoterol fumarate (Duaklir Pressair, Circassia) multidose inhaler is now available. Aclidinium bromide and formoterol fumarate is a fixed-dose, LAMA/LABA combination that is administered twice daily.
The therapy has been approved worldwide, and is based on data from a trio of Phase 3 studies: ACLIFORM, AUGMENT, and AMPLIFY. In addition, the therapy was tested in the Phase IV ASCENT-COPD study, showing effective reduction of exacerbations due to COPD.
The most common adverse reactions from aclidinium bromide and formoterol fumarate include upper respiratory tract infection, headache, and back pain versus placebo. Other reactions reported in clinical studies were cough, sinusitis, influenza, insomnia, dizziness, and more.
Circassia Pharmaceuticals launches DUAKLIR PRESSAIR (aclidinium/formoterol) for patients with Chronic Obstructive Pulmonary Disease (COPD) [news release]. Morrisville, NC; October 21, 2019: BusinessWire. https://www.businesswire.com/news/home/20191020005073/en. Accessed October 21, 2019.